NEW
YORK, June 25, 2024 /PRNewswire/ -- The global
inflammatory bowel disease market size is estimated to grow
by USD 7.61 billion from 2024-2028,
according to Technavio. The market is estimated to grow at a CAGR
of 5.48% during the forecast
period. Increasing incidence of ibd worldwide is
driving market growth, with a trend towards new launches
of ibd therapeutics. However, high cost of ibd therapeutics
poses a challenge. Key market players include Abbott
Laboratories, AbbVie Inc., AstraZeneca Plc, Aurobindo Pharma Ltd.,
Bausch Health Companies Inc., Baxter International Inc., Bayer AG,
Biocon Ltd., Eli Lilly and Co., F. Hoffmann La Roche Ltd.,
GlaxoSmithKline Plc, Johnson and Johnson Services Inc., Lupin Ltd.,
Merck and Co. Inc., Novartis AG, Pfizer Inc., Sanofi SA, Sun
Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries
Ltd., and Viatris Inc..
Get a detailed analysis on regions, market
segments, customer landscape, and companies - Click for the
snapshot of this report
Forecast
period
|
2024-2028
|
Base Year
|
2023
|
Historic
Data
|
2018 - 2022
|
Segment
Covered
|
Distribution Channel
(Offline and Online), Type (Crohn's disease and Ulcerative
colitis), and Geography (North America, Europe, Asia, and Rest of
World (ROW))
|
Region
Covered
|
North America, Europe,
Asia, and Rest of World (ROW)
|
Key companies
profiled
|
Abbott Laboratories,
AbbVie Inc., AstraZeneca Plc, Aurobindo Pharma Ltd., Bausch Health
Companies Inc., Baxter International Inc., Bayer AG, Biocon Ltd.,
Eli Lilly and Co., F. Hoffmann La Roche Ltd., GlaxoSmithKline Plc,
Johnson and Johnson Services Inc., Lupin Ltd., Merck and Co. Inc.,
Novartis AG, Pfizer Inc., Sanofi SA, Sun Pharmaceutical Industries
Ltd., Teva Pharmaceutical Industries Ltd., and Viatris
Inc.
|
Key Market Trends Fueling Growth
The global Inflammatory Bowel Disease (IBD) market is
experiencing significant growth due to the introduction of new
therapeutics. Pharmaceutical and biopharmaceutical companies are
increasing their research and development (R&D) spending,
leading to new product launches. For instance, Lupin launched
Mirabegron Extended-Release Tablets in the US in April 2024, and HUMIRA (Adalimumab), a TNF
blocker, received approval for pediatric use in February 2021. These advancements are expected to
continue driving market expansion during the forecast
period.
The Inflammatory Bowel Disease market is experiencing
significant growth due to the increasing prevalence of conditions
like Crohn's disease and ulcerative colitis. Pharmaceutical
companies are focusing on developing new treatments, such as
biologics and immunomodulators, to address the unmet needs of
patients. The use of technology, like telemedicine and digital
health solutions, is also on the rise to improve patient care and
accessibility. The market is competitive with key players including
Inhbit Therapeutics, Janssen Pharmaceuticals, and Pfizer.
Regulatory approvals and collaborations are key trends driving
market growth. The market is expected to continue growing due to
the high unmet medical need and ongoing research and development
efforts.
Research report provides comprehensive data on
impact of trend. For more details- Download a Sample
Report
Market Challenges
- The Inflammatory Bowel Disease (IBD) market is experiencing
growth due to the increasing use of biologics and small molecules
for treating chronic conditions like Crohn disease and ulcerative
colitis. The average cost of these therapies, including drugs,
doctor fees, and hospital visits, ranges from USD6,000 to USD32,000 per year. Biologics, which are
preferred for moderate to severe IBD, cost an average of
USD2,500 to USD5,500 per month. These rising patient expenses
may limit the market's expansion during the forecast period. For
instance, Pfizer's Xeljanz oral tablets for ulcerative colitis
treatment cost around USD4,900 to
USD5,000 for a 60-tablet supply.
- The Inflammatory Bowel Disease market faces several challenges.
These include the high incidence and prevalence of conditions like
Irritable Bowel Syndrome, Ulcerative Colitis, and Crohn's Disease.
Patients require proper diagnosis and treatment, which can be
complex due to the varied symptoms and causes. Pharmaceutical
companies aim to provide effective solutions, such as biologics and
small molecule therapies. However, the development of these
treatments is costly and time-consuming. Additionally, patient
compliance and access to care are significant challenges.
Regulatory requirements and competition further complicate the
market landscape. Overall, addressing these challenges requires a
collaborative effort from all stakeholders to improve patient
outcomes and advance the field of IBD research and treatment.
For more insights on driver and
challenges - Download a Sample Report
Segment Overview
This inflammatory bowel disease market report extensively covers
market segmentation by
- Distribution Channel
- Type
- 2.1 Crohn's disease
- 2.2 Ulcerative colitis
- Geography
- 3.1 North America
- 3.2 Europe
- 3.3 Asia
- 3.4 Rest of World (ROW)
1.1 Offline- The offline distribution channel plays
a vital role in the Inflammatory Bowel Disease (IBD) market,
accounting for a significant portion of sales. Brick-and-mortar
pharmacies and drugstores offer easy accessibility and convenience
for consumers, who prefer immediate availability and face-to-face
interactions with pharmacists. This segment benefits from consumer
preferences, providing discounts, promotional offers, and
personalized advice from licensed pharmacists. In regions with low
Internet penetration or privacy concerns, the offline channel is
essential for reaching a wider consumer base and building trust.
These factors contribute to the continued demand for the offline
distribution channel in the IBD market.
For more information on market segmentation with
geographical analysis including forecast (2024-2028) and historic
data (2018 - 2022) - Download a Sample Report
Research Analysis
The Inflammatory Bowel Disease (IBD) market encompasses
biological drugs that cater to conditions such as Crohn's disease
and ulcerative colitis, which are characterized by environmental
triggers and genetic predisposition. These diseases cause chronic
inflammation in the gastrointestinal tract, leading to symptoms
like abdominal pain, diarrhea, and weight loss. Biological drugs
like Cimzia, Entyvio, JAK inhibitors, and Janus kinase inhibitor
(Jyseleca) play a significant role in managing IBD. Industrialized
countries have a high prevalence of IBD due to their healthcare
systems and services, which facilitate the diagnosis and treatment
of these conditions by healthcare professionals in healthcare
institutes. Infections are also known to trigger IBD flare-ups,
making the development of effective treatments a priority. Ferring
Pharmaceuticals and Lilly are among the numerous entities involved
in the research and development of IBD treatments, with CytoReason
contributing through advanced analytics to improve clinical trial
outcomes.
Market Research Overview
The Inflammatory Bowel Disease (IBD) market encompasses a range
of chronic gastrointestinal conditions, including Crohn's disease
and ulcerative colitis. These disorders are characterized by
inflammation in the digestive tract, leading to abdominal pain,
diarrhea, and weight loss. The global IBD market is driven by
increasing prevalence rates, particularly in developed regions.
Factors fueling market growth include rising awareness, improved
diagnosis, and the development of novel therapeutic approaches.
Entities such as biotechnology companies, academic institutions,
and research organizations are actively engaged in advancing the
understanding of IBD etiology and developing new treatments. The
market landscape is further shaped by regulatory initiatives and
reimbursement policies. Symptomatic management and disease
remission are key objectives in IBD care, with a focus on
optimizing patient quality of life.
Table of Contents:
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation
- Distribution Channel
-
- Type
-
- Crohn's Disease
- Ulcerative Colitis
- Geography
-
- North America
- Europe
- Asia
- Rest Of World (ROW)
7 Customer Landscape
8 Geographic Landscape
9 Drivers, Challenges, and Trends
10 Company Landscape
11 Company Analysis
12 Appendix
About Technavio
Technavio is a leading global technology research and advisory
company. Their research and analysis focuses on emerging market
trends and provides actionable insights to help businesses identify
market opportunities and develop effective strategies to optimize
their market positions.
With over 500 specialized analysts, Technavio's report library
consists of more than 17,000 reports and counting, covering 800
technologies, spanning across 50 countries. Their client base
consists of enterprises of all sizes, including more than 100
Fortune 500 companies. This growing client base relies on
Technavio's comprehensive coverage, extensive research, and
actionable market insights to identify opportunities in existing
and potential markets and assess their competitive positions within
changing market scenarios.
Contacts
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/
View original content to download
multimedia:https://www.prnewswire.com/news-releases/inflammatory-bowel-disease-market-size-is-set-to-grow-by-usd-7-61-billion-from-2024-2028--increasing-incidence-of-ibd-worldwide-to-boost-the-market-growth-technavio-302180170.html
SOURCE Technavio